Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HC-7366,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HiberCell Gets FDA Fast Track for HC-7366 in Relapsed AML
Details : HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. It is being evaluated for the treatment of r/r AML.
Product Name : HC-7366
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2024
Lead Product(s) : HC-7366,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HC-7366,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HiberCell Doses First Patient in Phase 1b Trial of HC-7366 in AML Treatment
Details : HC-7366 is a first-in-human, small molecule activator of the GCN2 kinase, which is being evaluated in combination with venetoclax and azacitidine in AML patients.
Product Name : HC-7366
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : HC-7366,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HC-7366,Belzutifan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HiberCell Doses First Patient in Merck Collaboration for Advanced ccRCC
Details : HC-7366, a selective activator of general control nonderepressible 2 kinases, is under investigation with Welireg for clear cell renal cell carcinoma treatment.
Product Name : HC-7366
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2024
Lead Product(s) : HC-7366,Belzutifan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HC-7366,Belzutifan
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to evaluate HiberCell's HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor for the treatment of clear cell renal cell carcinom...
Product Name : HC-7366
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 12, 2023
Lead Product(s) : HC-7366,Belzutifan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)
Details : HC-7366, a first-in-class, first-in-human GCN2 activator. In preclinical studies, HC-7366 was observed to have robust anti-tumor and immunomodulatory activity in a variety of models of solid tumors and hematological malignancies.
Product Name : HC-7366
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2023
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
Details : The first-in-human Phase 1a/b clinical trial, designed to establish maximum tolerated dose, while evaluating safety and tolerability, and to establish recommended Phase 2 dose for HC-7366, selective, orally bioavailable modulator of GNC2 in patients with...
Product Name : HC-7366
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2022
Details : The posters will present the immunomodulatory mechanisms of HC-7366, a differentiated selective, orally bioavailable activator of GCN2 (general controlled nonderepressible 2). HiberCell is currently conducting Phase 1 clinical trials in solid tumors for ...
Product Name : HC-7366
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2022